Safety of autologous umbilical cord blood therapy for acquired sensorineural hearing loss in children

Linda S. Baumgartner, Ernest Moore, David Shook, Steven Messina, Mary Clare Day, Jennifer Green, Rajesh Nandy, Michael Seidman, James E. Baumgartner

Research output: Contribution to journalArticle

Abstract

Background and Objectives: Sensorineural hearing loss (SNHL) in children is associated with neurocognitive morbidity. The cause of SNHL is a loss of hair cells in the organ of Corti. There are currently no reparative treatments for SNHL. Numerous studies suggest that cord blood mononuclear cells (human umbilical cord blood, hUCB) allow at least partial restoration of SNHL by enabling repair of a damaged organ of Corti. Our objective is to determine if hUCB is a safe treatment for moderate to severe acquired SNHL in children. Subjects and Methods: Eleven children aged 6 months to 6 years with moderate to severe acquired SNHL were treated with intravenous autologous hUCB. The cell dose ranged from 8 to 30 million cells/kg body weight. Safety was assessed by measuring systemic hemodynamics during hUCB infusion. Infusion-related toxicity was evaluated by measuring neurologic, hepatic, renal and pulmonary function before and after infusion. Auditory function, auditory verbal language assessments and MRI with diffusion tensor imaging (DTI) were obtained before and after treatment. Results: All patients survived, and there were no adverse events. No infusionrelated changes in hemodynamics occurred. No infusion-related toxicity was recorded. Five subjects experienced a reduction in auditory brainstem response (ABR) thresholds. Four of those 5 subjects also experienced an improvement in cochlear nerve latencies. Comparison of MRI with DTI sequences obtained before and after treatment revealed increased fractional anisotropy in the primary auditory cortex in three of five subjects with reduced ABR thresholds. Statistically significant (p < 0.05) reductions in ABR thresholds were identified. Conclusions: TIntravenous hUCB is feasible and safe in children with SNHL.

Original languageEnglish
Pages (from-to)209-222
Number of pages14
JournalJournal of Audiology and Otology
Volume22
Issue number4
DOIs
StatePublished - 1 Oct 2018

Fingerprint

Sensorineural Hearing Loss
Fetal Blood
Safety
Brain Stem Auditory Evoked Potentials
Organ of Corti
Diffusion Tensor Imaging
Therapeutics
Hemodynamics
Cochlear Nerve
Auditory Cortex
Alopecia
Anisotropy
Nervous System
Blood Cells
Language
Body Weight
Morbidity
Kidney
Lung
Liver

Keywords

  • Auditory brainstem response
  • Diffusion tensor imaging
  • Fractional anisotropy
  • Human umbilical cord blood
  • Mesenchymal stem cells
  • Mononuclear fraction
  • Otoacoustic emission
  • Sensorineural hearing loss

Cite this

Baumgartner, L. S., Moore, E., Shook, D., Messina, S., Day, M. C., Green, J., ... Baumgartner, J. E. (2018). Safety of autologous umbilical cord blood therapy for acquired sensorineural hearing loss in children. Journal of Audiology and Otology, 22(4), 209-222. https://doi.org/10.7874/jao.2018.00115
Baumgartner, Linda S. ; Moore, Ernest ; Shook, David ; Messina, Steven ; Day, Mary Clare ; Green, Jennifer ; Nandy, Rajesh ; Seidman, Michael ; Baumgartner, James E. / Safety of autologous umbilical cord blood therapy for acquired sensorineural hearing loss in children. In: Journal of Audiology and Otology. 2018 ; Vol. 22, No. 4. pp. 209-222.
@article{6ec1087712c141a2810664810fcfbf44,
title = "Safety of autologous umbilical cord blood therapy for acquired sensorineural hearing loss in children",
abstract = "Background and Objectives: Sensorineural hearing loss (SNHL) in children is associated with neurocognitive morbidity. The cause of SNHL is a loss of hair cells in the organ of Corti. There are currently no reparative treatments for SNHL. Numerous studies suggest that cord blood mononuclear cells (human umbilical cord blood, hUCB) allow at least partial restoration of SNHL by enabling repair of a damaged organ of Corti. Our objective is to determine if hUCB is a safe treatment for moderate to severe acquired SNHL in children. Subjects and Methods: Eleven children aged 6 months to 6 years with moderate to severe acquired SNHL were treated with intravenous autologous hUCB. The cell dose ranged from 8 to 30 million cells/kg body weight. Safety was assessed by measuring systemic hemodynamics during hUCB infusion. Infusion-related toxicity was evaluated by measuring neurologic, hepatic, renal and pulmonary function before and after infusion. Auditory function, auditory verbal language assessments and MRI with diffusion tensor imaging (DTI) were obtained before and after treatment. Results: All patients survived, and there were no adverse events. No infusionrelated changes in hemodynamics occurred. No infusion-related toxicity was recorded. Five subjects experienced a reduction in auditory brainstem response (ABR) thresholds. Four of those 5 subjects also experienced an improvement in cochlear nerve latencies. Comparison of MRI with DTI sequences obtained before and after treatment revealed increased fractional anisotropy in the primary auditory cortex in three of five subjects with reduced ABR thresholds. Statistically significant (p < 0.05) reductions in ABR thresholds were identified. Conclusions: TIntravenous hUCB is feasible and safe in children with SNHL.",
keywords = "Auditory brainstem response, Diffusion tensor imaging, Fractional anisotropy, Human umbilical cord blood, Mesenchymal stem cells, Mononuclear fraction, Otoacoustic emission, Sensorineural hearing loss",
author = "Baumgartner, {Linda S.} and Ernest Moore and David Shook and Steven Messina and Day, {Mary Clare} and Jennifer Green and Rajesh Nandy and Michael Seidman and Baumgartner, {James E.}",
year = "2018",
month = "10",
day = "1",
doi = "10.7874/jao.2018.00115",
language = "English",
volume = "22",
pages = "209--222",
journal = "Journal of Audiology and Otology",
issn = "2384-1621",
publisher = "Korean Audiological Society",
number = "4",

}

Baumgartner, LS, Moore, E, Shook, D, Messina, S, Day, MC, Green, J, Nandy, R, Seidman, M & Baumgartner, JE 2018, 'Safety of autologous umbilical cord blood therapy for acquired sensorineural hearing loss in children', Journal of Audiology and Otology, vol. 22, no. 4, pp. 209-222. https://doi.org/10.7874/jao.2018.00115

Safety of autologous umbilical cord blood therapy for acquired sensorineural hearing loss in children. / Baumgartner, Linda S.; Moore, Ernest; Shook, David; Messina, Steven; Day, Mary Clare; Green, Jennifer; Nandy, Rajesh; Seidman, Michael; Baumgartner, James E.

In: Journal of Audiology and Otology, Vol. 22, No. 4, 01.10.2018, p. 209-222.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Safety of autologous umbilical cord blood therapy for acquired sensorineural hearing loss in children

AU - Baumgartner, Linda S.

AU - Moore, Ernest

AU - Shook, David

AU - Messina, Steven

AU - Day, Mary Clare

AU - Green, Jennifer

AU - Nandy, Rajesh

AU - Seidman, Michael

AU - Baumgartner, James E.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Background and Objectives: Sensorineural hearing loss (SNHL) in children is associated with neurocognitive morbidity. The cause of SNHL is a loss of hair cells in the organ of Corti. There are currently no reparative treatments for SNHL. Numerous studies suggest that cord blood mononuclear cells (human umbilical cord blood, hUCB) allow at least partial restoration of SNHL by enabling repair of a damaged organ of Corti. Our objective is to determine if hUCB is a safe treatment for moderate to severe acquired SNHL in children. Subjects and Methods: Eleven children aged 6 months to 6 years with moderate to severe acquired SNHL were treated with intravenous autologous hUCB. The cell dose ranged from 8 to 30 million cells/kg body weight. Safety was assessed by measuring systemic hemodynamics during hUCB infusion. Infusion-related toxicity was evaluated by measuring neurologic, hepatic, renal and pulmonary function before and after infusion. Auditory function, auditory verbal language assessments and MRI with diffusion tensor imaging (DTI) were obtained before and after treatment. Results: All patients survived, and there were no adverse events. No infusionrelated changes in hemodynamics occurred. No infusion-related toxicity was recorded. Five subjects experienced a reduction in auditory brainstem response (ABR) thresholds. Four of those 5 subjects also experienced an improvement in cochlear nerve latencies. Comparison of MRI with DTI sequences obtained before and after treatment revealed increased fractional anisotropy in the primary auditory cortex in three of five subjects with reduced ABR thresholds. Statistically significant (p < 0.05) reductions in ABR thresholds were identified. Conclusions: TIntravenous hUCB is feasible and safe in children with SNHL.

AB - Background and Objectives: Sensorineural hearing loss (SNHL) in children is associated with neurocognitive morbidity. The cause of SNHL is a loss of hair cells in the organ of Corti. There are currently no reparative treatments for SNHL. Numerous studies suggest that cord blood mononuclear cells (human umbilical cord blood, hUCB) allow at least partial restoration of SNHL by enabling repair of a damaged organ of Corti. Our objective is to determine if hUCB is a safe treatment for moderate to severe acquired SNHL in children. Subjects and Methods: Eleven children aged 6 months to 6 years with moderate to severe acquired SNHL were treated with intravenous autologous hUCB. The cell dose ranged from 8 to 30 million cells/kg body weight. Safety was assessed by measuring systemic hemodynamics during hUCB infusion. Infusion-related toxicity was evaluated by measuring neurologic, hepatic, renal and pulmonary function before and after infusion. Auditory function, auditory verbal language assessments and MRI with diffusion tensor imaging (DTI) were obtained before and after treatment. Results: All patients survived, and there were no adverse events. No infusionrelated changes in hemodynamics occurred. No infusion-related toxicity was recorded. Five subjects experienced a reduction in auditory brainstem response (ABR) thresholds. Four of those 5 subjects also experienced an improvement in cochlear nerve latencies. Comparison of MRI with DTI sequences obtained before and after treatment revealed increased fractional anisotropy in the primary auditory cortex in three of five subjects with reduced ABR thresholds. Statistically significant (p < 0.05) reductions in ABR thresholds were identified. Conclusions: TIntravenous hUCB is feasible and safe in children with SNHL.

KW - Auditory brainstem response

KW - Diffusion tensor imaging

KW - Fractional anisotropy

KW - Human umbilical cord blood

KW - Mesenchymal stem cells

KW - Mononuclear fraction

KW - Otoacoustic emission

KW - Sensorineural hearing loss

UR - http://www.scopus.com/inward/record.url?scp=85057209731&partnerID=8YFLogxK

U2 - 10.7874/jao.2018.00115

DO - 10.7874/jao.2018.00115

M3 - Article

AN - SCOPUS:85057209731

VL - 22

SP - 209

EP - 222

JO - Journal of Audiology and Otology

JF - Journal of Audiology and Otology

SN - 2384-1621

IS - 4

ER -